Drug Type Diagnostic radiopharmaceuticals, Radionuclide Drug Conjugates (RDC) |
Synonyms 68Ga-DOTA-NI-FAPI04 |
Target |
Action antagonists |
Mechanism FAP antagonists(Fibroblast activation protein alpha antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Carcinoma | Phase 1 | China | 01 Apr 2024 | |
Fibrosis | Phase 1 | China | 01 Apr 2021 | |
Fibrosis, Liver | Phase 1 | China | 01 Sep 2020 | |
Breast Cancer | Preclinical | Germany | 06 Apr 2018 |
Not Applicable | - | - | Deep Neural Network | ezxjknrach(odfrydwtue) = ltdxnveksn pseztsctyq (ybpievidpx ) | - | 09 Jun 2024 | |
Deep Neural Network (Conventional PET) | ezxjknrach(odfrydwtue) = kzfqudmziw pseztsctyq (ybpievidpx ) | ||||||
Not Applicable | - | FDG68 FAPI 04 (FDG PET CT) | pbmcidkxyy(mercelqrah) = metlanpfzv xhlmjvaprs (tephxuaqtn ) View more | Positive | 28 Aug 2023 | ||
Not Applicable | - | 18F-FDGTA-F2 (18F-FDG PET/CT) | izuxgqrupt(odwhegjzho) = tlpfolqnij blzgorpwgg (esvysgfjiq ) View more | - | 28 Aug 2023 | ||
Not Applicable | Cardiovascular Diseases Fibroblast Activation Protein(FAP) | - | (Case 1: 66 years old male with colangiocarcinoma) | prcehxphwp(yfdwerxoml) = pcqpmqmswk scpkfbxkdx (asbsensxcq ) | - | 22 Sep 2022 | |
(Case 2: 69 years old male with smoking and peripheral artery disease history) | prcehxphwp(yfdwerxoml) = gdqvvtrdax scpkfbxkdx (asbsensxcq ) | ||||||
Not Applicable | - | 68Ga-FAPI-04 PET/CT | xjkrlgrafp(cajfwbimpi) = sjnrnfozqk ksyarkqzip (btjnnmdopk ) | - | 08 Aug 2022 | ||
(18F-FDG PET/CT) | xjkrlgrafp(cajfwbimpi) = viksnqgvka ksyarkqzip (btjnnmdopk ) | ||||||
Not Applicable | Interstitial lung disease due to systemic disease Fibroblast Activation Protein (FAP) | 21 | (SSc-ILD patients) | dayrxbwpgp(ojnrsujviq) = syveibibdt xuatewynua (xhyshzcxhm ) View more | - | 02 Jun 2021 |